PTC Therapeutics receives positive opinion from CHMP

The Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion of PTC Therapeutics Inc.'s (Nasdaq: PTCT) nonsense mutation Duchenne muscular dystrophy treatment Translarna. Shares of Prosena Holding (Nasdaq: RNA), which is also developing a DMD treatment, soared $1.79 to close at $8.41. PTC Therapeutics stock leaped $4.71 to close at $20.03.